You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAclidinium
Accession NumberDB08897
TypeSmall Molecule
GroupsApproved
DescriptionAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Structure
Thumb
Synonyms
Aclidinium
External Identifiers
  • LAS-34273
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tudorza Genuairpowder (metered dose)400 mcginhalationAstrazeneca Canada Inc2013-09-13Not applicableCanada
Tudorza Pressairinhalant400 ug/1respiratory (inhalation)Astra Zeneca Pharmaceuticals Lp2015-07-01Not applicableUs
Tudorza Pressairinhalant400 ug/1respiratory (inhalation)Forest Laboratories, Inc.2012-07-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Bretaris GenuairNot Available
Eklira Genuair Not Available
Brand mixtures
NameLabellerIngredients
Duaklir GenuairAstrazeneca Canada Inc
Salts
Name/CASStructureProperties
Aclidinium Bromide
320345-99-1
Thumb
  • InChI Key: XLAKJQPTOJHYDR-QTQXQZBYSA-M
  • Monoisotopic Mass: 563.07996248
  • Average Mass: 564.555
DBSALT000003
Categories
UNIIK17VY42F6C
CAS number727649-81-2
WeightAverage: 484.651
Monoisotopic: 484.161624833
Chemical FormulaC26H30NO4S2
InChI KeyInChIKey=ASMXXROZKSBQIH-VITNCHFBSA-N
InChI
InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1
IUPAC Name
(3R)-3-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azabicyclo[2.2.2]octan-1-ium
SMILES
OC(C(=O)O[[email protected]]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinuclidines. These are compounds containing a 1-azabicyclo[2.2.2]octane moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinuclidines
Sub ClassNot Available
Direct ParentQuinuclidines
Alternative Parents
Substituents
  • Quinuclidine
  • Phenol ether
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiophene
  • Tertiary alcohol
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationAclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
PharmacodynamicsAclidinium does not prolong the QTc interval or have significant effects on cardiac rhythm.
Mechanism of actionAclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
Related Articles
AbsorptionBioavailability, healthy subjects = 6%; T max, healthy subjects = 10 minutes; Time to steady state, healthy subjects = 2 days;
Volume of distribution

Following IV administration, the volume of distribution is 300 L

Protein bindingNot Available
Metabolism

The major route of metabolism of aclidinium bromide is hydrolysis, which occurs both chemically and enzymatically by esterases in the plasma. Aclidinium bromide is rapidly and extensively hydrolyzed to its alcohol and dithienylglycolic acid derivatives, neither of which binds to muscarinic receptors and are pharmacologically inactive.

Route of eliminationIntravenously administered radiolabelled aclidinium bromide was administered to healthy volunteers and was extensively metabolized with 1% excreted as unchanged aclidinium. Approximately 54% to 65% of the radioactivity was excreted in urine and 20% to 33% of the dose was excreted in feces. The combined results indicated that almost the entire aclidinium bromide dose was eliminated by hydrolysis. After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose.
Half lifePlasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). Effective half-life = 5-8 hours.
Clearance

Total clearance, IV dose, young healthy subjects = 170 L/h (inter-individual variability of 36%)

ToxicityMost common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9907
Blood Brain Barrier+0.8883
Caco-2 permeable-0.6509
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor INon-inhibitor0.8103
P-glycoprotein inhibitor IINon-inhibitor0.6449
Renal organic cation transporterInhibitor0.6092
CYP450 2C9 substrateNon-substrate0.7784
CYP450 2D6 substrateNon-substrate0.809
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8536
CYP450 2C9 inhibitorNon-inhibitor0.8817
CYP450 2D6 inhibitorNon-inhibitor0.5813
CYP450 2C19 inhibitorNon-inhibitor0.8022
CYP450 3A4 inhibitorNon-inhibitor0.7154
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.808
Ames testNon AMES toxic0.7753
CarcinogenicityNon-carcinogens0.9292
BiodegradationReady biodegradable0.6794
Rat acute toxicity2.6182 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7765
hERG inhibition (predictor II)Non-inhibitor0.6484
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Powder (metered dose)inhalation
Powder (metered dose)inhalation400 mcg
Inhalantrespiratory (inhalation)400 ug/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5840279 No1996-06-212016-06-21Us
US6071498 No1996-06-212016-06-21Us
US6681768 No2002-08-072022-08-07Us
US6750226 No2000-09-052020-09-05Us
US7078412 No2000-07-162020-07-16Us
US8051851 No2007-04-222027-04-22Us
US9056100 No2000-07-072020-07-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP3.07ALOGPS
logP0.45ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)10.35ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.76 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity141.33 m3·mol-1ChemAxon
Polarizability52.09 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. [PubMed:23641160 ]
  2. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. [PubMed:23566013 ]
  3. Jones P: Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. [PubMed:23553509 ]
External Links
ATC CodesR03AL05R03BB05
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (1.25 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with 1,10-Phenanthroline.
AlfentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ambenonium.
Anisotropine MethylbromideAclidinium may increase the anticholinergic activities of Anisotropine Methylbromide.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Aclidinium.
Atracurium besylateAclidinium may increase the anticholinergic activities of Atracurium besylate.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Aclidinium.
AtropineAclidinium may increase the anticholinergic activities of Atropine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Aclidinium.
BenactyzineAclidinium may increase the anticholinergic activities of Benactyzine.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Aclidinium.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Aclidinium.
BenzatropineAclidinium may increase the anticholinergic activities of Benzatropine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Aclidinium.
BezitramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Bezitramide.
BiperidenAclidinium may increase the anticholinergic activities of Biperiden.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Aclidinium.
Botulinum Toxin Type AAclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BAclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.
ChlorphenoxamineAclidinium may increase the anticholinergic activities of Chlorphenoxamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Aclidinium.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Aclidinium.
CimetropiumAclidinium may increase the anticholinergic activities of Cimetropium.
CodeineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Codeine.
CoumaphosThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Coumaphos.
CyclopentolateAclidinium may increase the anticholinergic activities of Cyclopentolate.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Aclidinium.
DarifenacinAclidinium may increase the anticholinergic activities of Darifenacin.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Aclidinium.
DecamethoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Demecarium.
DesloratadineAclidinium may increase the anticholinergic activities of Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Aclidinium.
DexetimideAclidinium may increase the anticholinergic activities of Dexetimide.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Aclidinium.
DextromoramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Dichlorvos.
DicyclomineAclidinium may increase the anticholinergic activities of Dicyclomine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Aclidinium.
DihydrocodeineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Aclidinium is combined with DPDPE.
DronabinolAclidinium may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Edrophonium.
EluxadolineAclidinium may increase the constipating activities of Eluxadoline.
EthopropazineAclidinium may increase the anticholinergic activities of Ethopropazine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Aclidinium.
EthylmorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fentanyl.
FenthionThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Fenthion.
FesoterodineAclidinium may increase the anticholinergic activities of Fesoterodine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Aclidinium.
GalantamineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Galantamine.
Gallamine TriethiodideAclidinium may increase the anticholinergic activities of Gallamine Triethiodide.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Aclidinium.
Ginkgo bilobaThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.
GlycopyrroniumAclidinium may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Aclidinium is combined with Heroin.
HexamethoniumAclidinium may increase the anticholinergic activities of Hexamethonium.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Aclidinium.
HomatropineAclidinium may increase the anticholinergic activities of Homatropine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Aclidinium.
Huperzine AThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aclidinium.
HydrocodoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Aclidinium.
HydromorphoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone.
HyoscyamineAclidinium may increase the anticholinergic activities of Hyoscyamine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Aclidinium.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Aclidinium.
Ipratropium bromideAclidinium may increase the anticholinergic activities of Ipratropium bromide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Aclidinium.
IsoflurophateThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Aclidinium.
KetobemidoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ketobemidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Lofentanil.
MalathionThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Malathion.
MecamylamineAclidinium may increase the anticholinergic activities of Mecamylamine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Aclidinium.
MefloquineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadyl Acetate.
MethanthelineAclidinium may increase the anticholinergic activities of Methantheline.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Aclidinium.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.
MetixeneAclidinium may increase the anticholinergic activities of Metixene.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Aclidinium.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Aclidinium.
MianserinMianserin may increase the anticholinergic activities of Aclidinium.
MinaprineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Aclidinium is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.
N-butylscopolammonium bromideAclidinium may increase the anticholinergic activities of N-butylscopolammonium bromide.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Aclidinium.
NabiloneAclidinium may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Neostigmine.
NormethadoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Normethadone.
NVA237Aclidinium may increase the anticholinergic activities of NVA237.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Aclidinium.
OpiumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Opium.
OrphenadrineAclidinium may increase the anticholinergic activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Aclidinium.
OxybutyninAclidinium may increase the anticholinergic activities of Oxybutynin.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Aclidinium.
OxycodoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxymorphone.
OxyphenoniumAclidinium may increase the anticholinergic activities of Oxyphenonium.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Aclidinium.
PancuroniumAclidinium may increase the anticholinergic activities of Pancuronium.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Aclidinium.
PentazocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.
PentoliniumAclidinium may increase the anticholinergic activities of Pentolinium.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Aclidinium.
PethidineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Physostigmine.
PipecuroniumAclidinium may increase the anticholinergic activities of Pipecuronium.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Aclidinium.
PirenzepineAclidinium may increase the anticholinergic activities of Pirenzepine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Aclidinium.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Aclidinium.
Potassium ChlorideAclidinium may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Aclidinium.
ProcyclidineAclidinium may increase the anticholinergic activities of Procyclidine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Aclidinium.
PropanthelineAclidinium may increase the anticholinergic activities of Propantheline.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Aclidinium.
PyridostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Aclidinium.
QuinidineAclidinium may increase the anticholinergic activities of Quinidine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Aclidinium.
RamosetronAclidinium may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Remifentanil.
RivastigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Rivastigmine.
ScopolamineAclidinium may increase the anticholinergic activities of Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aclidinium.
Scopolamine butylbromideAclidinium may increase the anticholinergic activities of Scopolamine butylbromide.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Aclidinium.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.
SolifenacinAclidinium may increase the anticholinergic activities of Solifenacin.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Aclidinium.
SufentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Aclidinium.
TacrineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tapentadol.
TiotropiumAclidinium may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Aclidinium.
TolterodineAclidinium may increase the anticholinergic activities of Tolterodine.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Aclidinium.
TopiramateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Aclidinium.
TrihexyphenidylAclidinium may increase the anticholinergic activities of Trihexyphenidyl.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Aclidinium.
TrimethaphanAclidinium may increase the anticholinergic activities of Trimethaphan.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Aclidinium.
TropicamideAclidinium may increase the anticholinergic activities of Tropicamide.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Aclidinium.
TrospiumAclidinium may increase the anticholinergic activities of Trospium.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Aclidinium.
TubocurarineAclidinium may increase the anticholinergic activities of Tubocurarine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Aclidinium.
UmeclidiniumAclidinium may increase the anticholinergic activities of Umeclidinium.
VecuroniumAclidinium may increase the anticholinergic activities of Vecuronium.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Aclidinium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. [PubMed:23566013 ]
Comments
comments powered by Disqus
Drug created on June 04, 2013 17:58 / Updated on September 28, 2016 02:28